Sucralfate — Veterinary Vademecum Drug Reference

Dosage & Administration Guidelines

Species	Route	Dose	Frequency	Duration & Clinical Notes
Dog	PO	0.5-1 g per dog (or 20-40 mg/kg)	q8h (every 8 hours)	Duration: 4-6 weeks or as directed Notes: Administer on an empty stomach, at least 1 hour before or 2 hours after meals. For ulcer treatment, continue until healing is confirmed.
Cat	PO	250-500 mg per cat (or 20-40 mg/kg)	q8-12h (every 8-12 hours)	Duration: 4-6 weeks or as directed Notes: Administer on an empty stomach. May be given as a slurry if the cat refuses tablets.
Horse	PO	10-20 mg/kg (or 2-4 g per horse)	q6-8h (every 6-8 hours)	Duration: 4-6 weeks or as directed Notes: Administer via nasogastric tube or as an oral paste. For EGUS, combine with acid suppressants for optimal healing.
Cattle	PO	10-20 mg/kg	q8-12h	Duration: 5-7 days or as directed Notes: Use with caution in ruminants; may affect rumen function. Administer via oral drench.
Small Ruminants (sheep, goats)	PO	10-20 mg/kg	q8-12h	Duration: 5-7 days or as directed Notes: Use with caution in ruminants; may affect rumen function. Administer via oral drench.
Rabbit	PO	25-50 mg/kg	q8-12h	Duration: 5-7 days or as directed Notes: Administer as a suspension. Monitor for gastrointestinal stasis.
Birds/Poultry	PO	25-50 mg/kg	q8-12h	Duration: 5-7 days or as directed Notes: Administer via crop gavage. Use with caution in birds with renal impairment.
Exotic/Other (reptiles, small mammals)	PO	25-50 mg/kg	q8-12h	Duration: 5-7 days or as directed Notes: Dose based on species-specific requirements. Administer as a suspension.

Clinical Indications & Species Uses

General Indications

Gastric and duodenal ulcers
Esophagitis
Gastroesophageal reflux
Gastritis
Prevention of stress ulcers
Adjunct in Helicobacter therapy

Dog (Canine)

Gastric ulcers
Duodenal ulcers
Esophagitis
Gastroesophageal reflux
Gastritis
Prevention of stress ulcers
Adjunct in Helicobacter therapy

Cat (Feline)

Gastric ulcers
Esophagitis
Gastroesophageal reflux
Gastritis
Prevention of stress ulcers

Horse (Equine)

Gastric ulcers (equine gastric ulcer syndrome)
Duodenal ulcers
Esophagitis
Gastritis

Cattle (Bovine)

Abomasal ulcers
Gastritis
Esophagitis

Small Ruminants (Sheep / Goat)

Abomasal ulcers
Gastritis
Esophagitis

Rabbit & Small Mammals

Gastric ulcers
Gastritis
Esophagitis
Gastrointestinal stasis (adjunct)

Avian & Poultry

Gastric ulcers
Gastritis
Esophagitis
Proventricular ulceration

Exotic & Other Species

Gastric ulcers
Gastritis
Esophagitis
Gastrointestinal ulceration in reptiles and small mammals

Pharmacology & Mechanism of Action

Drug Class: Gastroprotective Agent | Pharmacological Group: Sucralfate (basic aluminum sucrose sulfate complex)

Mechanism of Action: Sucralfate is a cytoprotective agent that forms a viscous, adhesive gel when exposed to gastric acid. The drug polymerizes and binds selectively to ulcerated or inflamed gastrointestinal mucosa, creating a protective barrier against acid, pepsin, and bile salts. It also inhibits pepsin activity, adsorbs bile acids, and stimulates local production of prostaglandins and mucus, promoting mucosal healing. The drug does not neutralize gastric acid significantly.

Pharmacodynamics: Sucralfate exerts its effects locally in the gastrointestinal tract. It adheres to ulcer craters and erosions, protecting them from further damage. It also enhances mucosal defense mechanisms, including increasing mucus secretion and mucosal blood flow. The drug has minimal systemic absorption and acts primarily at the site of application. Its efficacy is dependent on an acidic environment, as the drug requires acid to polymerize and become active.

⚡ Pharmacokinetics Summary

Absorption: Sucralfate is minimally absorbed from the gastrointestinal tract. Less than 3-5% of the administered dose is absorbed systemically, with the remainder excreted in feces. The absorbed fraction is primarily excreted in urine as aluminum and sucrose sulfate.

Distribution: Due to minimal absorption, systemic distribution is negligible. The drug remains largely within the gastrointestinal lumen, where it binds to mucosal surfaces.

Metabolism: Sucralfate is not metabolized systemically. It undergoes minimal hydrolysis in the stomach, releasing aluminum and sucrose sulfate, which are poorly absorbed.

Excretion: The unabsorbed drug is excreted in feces. The small absorbed fraction is excreted in urine. Aluminum may accumulate in patients with renal impairment.

Half-Life: The half-life of sucralfate is not clinically relevant due to minimal systemic absorption. The local effect lasts for up to 6 hours after administration.

Bioavailability: Oral bioavailability is less than 5%.

Protein Binding: Not applicable due to minimal systemic absorption.

Available Formulations & Strengths

Oral Tablet 1 g (1000 mg) (PO)

Oral Suspension 1 g/10 mL (100 mg/mL) (PO)

Oral Paste (veterinary) Various (e.g., 2 g/30 mL) (PO)

Contraindications & Clinical Warnings

Contraindications:

Hypersensitivity to sucralfate or any component
Patients with renal impairment (due to aluminum accumulation)
Concurrent use with other medications that require gastric acid for absorption (e.g., certain antifungals, antibiotics) unless separated by at least 2 hours
Intestinal obstruction or ileus (relative contraindication)

Warnings & Clinical Precautions:

Use with caution in patients with renal insufficiency; monitor aluminum levels if long-term therapy.
May cause constipation; ensure adequate hydration.
Administer on an empty stomach for optimal effect.
Separate from other oral medications by at least 2 hours to avoid binding and reduced absorption.
In ruminants, may alter rumen flora; monitor for digestive disturbances.
Not recommended for use in pregnant or lactating animals unless benefits outweigh risks (limited safety data).
Use with caution in animals with gastrointestinal obstruction or motility disorders.

Adverse Effects & Reactions

Common:

Constipation
Dry mouth
Nausea
Vomiting (rare in animals)

Serious / Severe:

Bezoar formation (rare)
Aluminum toxicity (with prolonged use in renal impairment)
Hyperaluminemia
Intestinal obstruction (rare)

Rare:

Hypophosphatemia (with long-term use)
Metabolic alkalosis (with concurrent antacids)
Allergic reactions

Key Drug Interactions

Interacting Drug / Class	Clinical Effect & Mechanism	Severity
Antacids (e.g., aluminum/magnesium hydroxide)	May reduce the efficacy of sucralfate by altering gastric pH; separate administration by at least 1 hour.	Moderate
Fluoroquinolones (e.g., enrofloxacin, ciprofloxacin)	Sucralfate binds to fluoroquinolones, reducing their absorption and efficacy.	High
Tetracyclines (e.g., doxycycline)	Reduced absorption of tetracyclines due to binding with sucralfate.	High
Digoxin	Sucralfate may reduce digoxin absorption.	Moderate
Phenytoin	Reduced absorption of phenytoin.	Moderate
Theophylline	Reduced absorption of theophylline.	Moderate
Ketoconazole and other azole antifungals	Reduced absorption of azoles due to binding.	High
Levothyroxine	Reduced absorption of levothyroxine.	Moderate
Warfarin	Sucralfate may reduce warfarin absorption, potentially decreasing anticoagulant effect.	Moderate

Overdose & Toxicity Management

Signs of Toxicity:

Constipation
Gastrointestinal obstruction (rare)
Aluminum toxicity (with chronic overdose)
Hypophosphatemia

Emergency Treatment Protocol: Treatment is symptomatic and supportive. Discontinue the drug, ensure adequate hydration, and manage constipation with laxatives if needed. In cases of suspected aluminum toxicity, monitor serum aluminum levels and consider chelation therapy. There is no specific antidote.

Food Animal Withdrawal Times

🥩 Meat: 0 days🥛 Milk: 0 days🥚 Eggs: 0 days

Sucralfate is not systemically absorbed and is unlikely to leave residues in edible tissues. However, for food animals, consult regulatory guidelines and consider withdrawal times of 0 days for meat, milk, and eggs. Always follow local regulations.

Storage, Handling & Regulatory Information

Storage Temperature: Store at room temperature (15-30°C / 59-86°F).

Handling & Special Conditions: Keep container tightly closed. Protect from moisture. Do not freeze oral suspension.

Dispensing Status: Prescription Required (Rx Only)

Approval Status: Approved for human use; not FDA-approved for veterinary species, but widely used in veterinary medicine.

Extra-Label (Off-Label) Use: In the US, sucralfate is not FDA-approved for veterinary use, but it is commonly used extra-label in animals. Extra-label use must comply with AMDUCA regulations, requiring a valid veterinarian-client-patient relationship and appropriate withdrawal times for food animals.

Clinical Pearls & Practice Notes

💡 Clinical Insights: Sucralfate is a valuable gastroprotective agent for managing gastric and duodenal ulcers, esophagitis, and gastritis in various animal species. It is particularly useful in dogs, cats, and horses. For optimal efficacy, administer on an empty stomach, at least 1 hour before meals or other oral medications. In horses, it is often used in combination with proton pump inhibitors (e.g., omeprazole) for equine gastric ulcer syndrome. In ruminants, use with caution due to potential effects on rumen function. Always separate from other oral medications by at least 2 hours to avoid drug interactions. Monitor for constipation, especially in small animals. In patients with renal impairment, consider alternative therapies or monitor aluminum levels. Sucralfate is generally well-tolerated, but its use should be based on a definitive diagnosis and appropriate therapeutic plan.

References & Literature

📚 Plumb's Veterinary Drug Handbook
📚 Papich Veterinary Pharmacology and Therapeutics
📚 Compendium of Veterinary Products (CVP)